We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 3.34 | 2.60% | 132.00 | 131.965 | 128.63 | 128.66 | 7,236,513 | 00:58:07 |
From May 2019 to May 2024
By Colin Kellaher
Merck & Co. (MRK) on Monday said it agreed to buy Tilos Therapeutics, a privately held biopharmaceutical company developing therapeutics for the treatment of cancer, fibrosis and autoimmune diseases, for up to $773 million.
The Kenilworth, N.J., drug maker said the figure includes an upfront payment and contingent milestone payments.
Merck said Tilos is developing therapeutics targeting TGF<BETA>, a potent cytokine believed to play an important role in the development of cancer and fibrotic diseases.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 10, 2019 07:22 ET (11:22 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
